Innovative Imperial spin-out biopharmaceutical company teams up with BioVectra

The agreement, which follows hard on the heels of PolyTherics’ recent successful fundraising of over £2 million, will see BioVectra manufacturing high quality cGMP MPEG reagents to support clients’ clinical development of PolyTherics’ novel PEGylation technology. BioVectra will also market the PEGylation technology to its client base in North America.

PolyTherics has developed patent-protected proprietary technologies and expertise in the modification of drugs to improve their performance. The Company’s innovative PEGylation technology, known as TheraPEG, can extend the half-life of novel and existing protein drugs. The TheraPEG approach produces an improvement in biological activity and a higher yield than the existing PEGylation technologies. This means that drugs, such as Interferon, stay active in the body for longer, enabling longer periods between doses. Patients can therefore be treated less often, with fewer side-effects and at lower cost.

The market for traditional PEGylation has expanded considerably and PolyTherics’ TheraPEG technology is positioned both to address existing markets and open new markets, particularly in the antibody field. PolyTherics already has revenue-generating development contracts in place with several companies and is in discussion with a number of other parties.

Dr Keith Powell, CEO of PolyTherics, said: “We are delighted to have signed this agreement with BioVectra, who offer access to specialist custom polymer chemistry capabilities, a patented MPEG purification process and scaled manufacturing systems –the key components that are needed to support clients of our TheraPEG™ technology.

“We are currently in discussion with a number of biogeneric and pharmaceutical companies in Europe and the USA and there is significant interest in downstream applications for our TheraPEG technology. This agreement with BioVectra means that we can work with a highly competent manufacturer who will supply the highest quality MPEGs to meet our clients’ needs and comply with FDA standards. So we now have the tools to take our TheraPEG™ technology from the laboratory into the feasibility testing and manufacturing stages.”

Stephen Ball, Business Development Representative for BioVectra, said: “We are pleased to be working with PolyTherics to support the development of their innovative and important site specific TheraPEG technology. We look forward to deploying our capabilities in the manufacturing of high quality cGMP MPEG reagents to assist PolyTherics’ clients through clinical development of therapeutic proteins into post approval commercialization.”

Dale Zajicek, Chief Operating Officer of BioVectra, said: “We remain committed to supporting our PEGs business initiatives with technology that creates true value for our customers and their patients. The PolyTherics agreement is a clear example of this commitment.”

Media Contact

Margaret Henry alfa

More Information:

http://polytherics.co.uk

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors